Nuvig Therapeutics Appoints Dr. Alan Glicklich Chief Medical Officer

Physician and biopharmaceutical leadership executive with extensive experience in novel drug development, operations management, and team building October 04, 2023 09:00 AM Eastern Daylight Time REDWOOD CITY, Calif. – Nuvig Therapeutics, Inc., a private biotech company developing novel biologic therapeutics to treat inflammatory autoimmune diseases, announced today the appointment of Alan Glicklich, M.D., as Chief Medical Officer. Dr. Glicklich has more than 25 years of … Continue reading Nuvig Therapeutics Appoints Dr. Alan Glicklich Chief Medical Officer

Impact Newswire04/10/202326/06/2024

Global, United States

Sonoma Biotherapeutics Appoints Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, as Chief Medical Officer

Co-founder Fred Ramsdell, Ph.D., to retire from Chief Scientific Officer position September 29, 2023 07:00 AM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif. & SEATTLE – Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the appointments of Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, … Continue reading Sonoma Biotherapeutics Appoints Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, as Chief Medical Officer

Impact Newswire02/10/202326/06/2024